Article
Published 7 Nov 2025
Takeda And Innovent Biologics Enter Collaboration Agreement On IBI343 And IBI363 Cancer Drugs
Goodwin Procter LLP
Your search returned 6,519 results
Refine Your Search
Search Results
- Relevance
- Newest
- Oldest
Article
Published 7 Nov 2025
UPC Court Of Appeal Provides Framework For Enforcement By Penalty Payments
J A Kemp LLP
Article
Published 7 Nov 2025
Complete Response Letters In Transition: Navigating FDA's Transparency Policy And Manufacturing-Related Actions, And How To Respond
Arnold & Porter
Article
Published 6 Nov 2025
Benesch's Dental/DSO Intelligence Monthly Report: October 2025
Benesch Friedlander Coplan & Aronoff LLP
Article
Published 6 Nov 2025
Prefilled Syringe Presentation Of GSK's SHINGRIX Receives Positive CHMP Opinion
Goodwin Procter LLP
Article
Published 6 Nov 2025
Holland & Knight Health Dose: November 4, 2025
Holland & Knight
Article
Published 6 Nov 2025
European Bioeconomy Alliance Report Confirms Benefits Of Using First-Generation Biomass For Food, Fuels, And Chemicals In Europe
Bergeson & Campbell
Article
Published 6 Nov 2025
FDA Proposes To Eliminate Comparative Clinical Efficiency Studies For Biosimilars
Arnold & Porter
Article
Published 6 Nov 2025
California's New Allergen-Disclosure Law: A Sign Of Things To Come?
Hyman, Phelps, & McNamara
Article
Published 6 Nov 2025
Onshoring Drug Manufacturing: Insights From FDA's PreCheck Initiative And Public Meeting
Hyman, Phelps, & McNamara
Article
Published 6 Nov 2025
You've Got Mail, And Twice The Time To Respond! Two Device Companies Find Themselves With 30 Business Days To Respond To FDA's Warning Letters
Hyman, Phelps, & McNamara
Article
Published 6 Nov 2025
Bring Out Your Meds! Bring Out Your Meds!
Hyman, Phelps, & McNamara
Article
Published 6 Nov 2025
Where Have All The Good Guidance Gone?
Hyman, Phelps, & McNamara
Article
Published 6 Nov 2025
BIOSECURE Act Advances In The US Senate
Greenberg Traurig, LLP
Article
Published 6 Nov 2025
FDA Proposes To Remove Comparative Efficacy Studies To Accelerate Biosimilar Development
Jones Day
Article
Published 6 Nov 2025
The Profit Crunch: How US Policy Could Reshape Global Pharma Research And Development (R&D)
Alvarez & Marsal
Article
Published 5 Nov 2025
Senate Passes Revised Version Of The BIOSECURE Act
Hyman, Phelps, & McNamara
Article
Published 5 Nov 2025
HHS Divided: Can Consumers Be Trusted With Low-Risk Products?
Hyman, Phelps, & McNamara
Article
Published 5 Nov 2025
New FDA Guidance Could Speed Biosimilar Approvals And Cut Costs
Polsinelli LLP
Article
Published 4 Nov 2025
Key Healthcare And Life Sciences Regulatory Updates And Enforcement Trends In 2025 & Beyond
Buchanan Ingersoll & Rooney PC